Read your latest personalised notifications
No account yet? Start here
Don't miss out
Ok, got it
Deadline: Monday 11 June 2018, 23:59 (CET - Central European Time). No late submission will be accepted.
Draft Status: If you do not click on the submit button, your application will be saved in Draft Status. You will then be able to review it and submit it at a later time (but only before the deadline). NB: Applications that are in draft status after the deadline cannot be processed and therefore will not be considered for selection.
Changes and corrections: Once submitted, it is not possible to make any corrections to the application content or information (such as Presenter details, topic etc...). The ESC is not authorised to make changes to a submission. In order to correct your application you must withdraw it and submit a new corrected version prior to the deadline (See below for withdrawal procedure). Note that, such replacement of your application is not possible after the deadline. In the case of errors in your application discovered after the deadline, you may indicate the correction during the presentation at the congress.
Withdrawal: If you want to withdraw an application already submitted, please notify us as quickly as possible at firstname.lastname@example.org stating the title of the application to be withdrawn. Note that, withdrawals are still accepted after the submission deadline.
Select one topic from the list of topics which best describes the technology. Make sure you select the appropriate topic/best matching topic as this choice will determine which graders will review your application. Applications submitted under a topic that does not match the subject matter of the application may be given a lower score from reviewers.
The Technologies & solutions should either on the market, “ready for market” or in a late development stage (we are less interested in embryonic products). Examples of technologies/approaches that can be illustrated with practical user cases, and ideally have outcome studies rather than just user numbers/satisfaction data, will be prioritised.
The ESC Digital Health Selection Committee is requesting that submitters disclose all information pertaining to commercial promotion of a proprietary product and/or support relation with Research or Commercial Companies.
This declaration is mandatory.
In your application, you will need to describe who will use your technology: Patient/Doctor/Allied professional/Data Collection only/Researchers…
We recommend you to use the following structure to describe your technology in clearly identified sections:
All applications will be considered by a reviewing committee composed of 7 members (Nucleus of ESC Digital Health Committee).
Selection Criteria will consider
Submission of an application constitutes a commitment to present if accepted. Failure to present and register for the Congress, if not justified, will be identified as “no-show” and will jeopardize future acceptance of applications.
Submitter represents and warrants to the ESC that he/she/they is/are authorized to submit and present the technology and that the submission does not infringe upon any copyright, proprietary or personal right of any third party and/or any confidentiality obligations.
The submitter hereby affirms that the work submitted is based on thorough examination and investigation for accurateness.
If the application is accepted for presentation, the presenter will be asked to transfer and assign to the ESC free of charge, on a non-exclusive and worldwide basis, for fifteen years from the present submission the rights to edit, publish, reproduce, reformat, distribute in whole or in part the presentation given and prepare all type of derivative works such as press releases and/or educational products, using all communication tools and means, now known or hereinafter developed, including any and all digital means and any and all supports or forms of media, now known or hereinafter developed, in particular all paper, analog, digital, numerical and electronic media, including Internet, Intranet and Extranet sites and social media. This includes use in indexes or search databases in print, electronic, or other media.
The submitter signs for all Stakeholders that He/she accepts responsibility for the present rules for submission and presentation.
The Congress Programme Committee requests all Presenters to display a slide at the beginning of their presentation indicating disclosure information as applicable. This will allow the audience to take potential conflicts of interest into account when assessing the objectivity of the presentation.
A potential conflict of interest may arise from various relationships, past or present, such as employment, consultancy, investments and stock ownership, funding for research, family relationship, etc.
This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the article. Such relationships include, but are not limited to, employment by an industrial concern, ownership of stock, membership on a standing advisory council or committee, being on the board of directors, or being publicly associated with the company or its products. Other areas of real or perceived conflict of interest could include receiving honoraria or consulting fees or receiving grants or funds from such corporations or individuals representing such corporations.
By certifying that you have read and accepted these Submission rules, you also confirm having received the prior approval from all contributors and stakeholders to provide their data to the ESC.
The ESC implements personal data processing operations whose purpose is the registration, management and monitoring of your submission for ESC Congress 2018. The ESC may also use the data to inform you about the next ESC Congresses. The data is intended to the ESC Congress Team
The data is kept for fifteen years.
Pursuant to the Law on data processing and Civil Liberties 78-17 of 6 January 1978 modified and the Regulation (EU) 2016/679 of the European Parliament and of the Council of 27 April 2016, you have the absolute right to access, amend and oppose any use of this personal data and the right to limit processing and erasure within the framework allowed by the European Regulation by writing to the ESC at the address mentioned below:
European Society of CardiologyThe European Heart HouseLes Templiers2035 Route des CollesCS 80179 Biot06903 Sophia-Antipolis Cedex – France
You may, if you deem it necessary, file a claim with the supervisory authority.
For your information, the European Society of Cardiology has appointed a Data Protection Officer, who can be reached at the email address email@example.com
All the rules pertaining to the present submission are governed by and construed in accordance with the laws of France without regard to any conflicts of laws principles thereof that would require the application of the law of any other jurisdiction. Any disputes arising in relation hereto shall be submitted to the exclusive jurisdiction of the French Tribunal de Grande Instance located in Grasse, France.
If you have difficulties in submitting your application or if you need any further information, please contact the ESC Team at firstname.lastname@example.org
Our mission: To reduce the burden of cardiovascular disease.
© 2019 European Society of Cardiology. All rights reserved.